SCHEMBL4843503

SCHEMBL4843503

COCC(C)OC(=O)Nc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
RAB9A P51151 4/20 0.49
TP53 P04637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 3/20 0.47
HPGD P15428 3/20 0.47
HTT P42858 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
GAA P10253 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.46
ALOX12 P18054 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP3 P42574 1/20 0.46
MEN1 O00255 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17342587 0.89 ALDH1A1 (0.48) MAPTLMNAALDH1A1RAB9ATP53
SCHEMBL12407192 0.86 ALDH1A1 (0.53) MAPTLMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL14466318 0.84 MAPT (0.51) MAPTLMNAALDH1A1RAB9ATP53
SCHEMBL17346687 0.84 MAPT (0.51) MAPTLMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL10639437 0.83 RAB9A (0.50) MAPTLMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL10677828 0.83 RAB9A (0.52) MAPTRAB9ASMN1; SMN2NPC1HPGD
SCHEMBL10912953 0.82 CTSK (0.52) MAPTRAB9ASMN1; SMN2NPC1CASP3
SCHEMBL18353145 0.82 LMNA (0.49) MAPTLMNAALDH1A1RAB9ATP53
SCHEMBL750595 0.82 MAPT (0.49) MAPTLMNAALDH1A1RAB9ASMN1; SMN2
SCHEMBL18355346 0.82 LMNA (0.46) MAPTLMNAALDH1A1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445502-B2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS ALKERMES PHARMA IRELAND LTD (IE) 2022-09-28 EP disclosed
EP-1940785-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SmithKline Beecham Corporation (US) 2008-07-09 EP disclosed
WO-2007030761-A2 ACYCLIC 1,4-DIAMINES AND USES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2007-03-15 WO disclosed